MATURATION OF HEMOPOIETIC CELLS

Abstract: The invention concerns the use of IgE-binding factor (IgE-bf) for the stimulation of the maturation, i.e. of the differentiation and proliferation, of myeloid precursor cells in context with interleukin-1 (IL-1). The invention further concerns a pharmaceutical preparation comprising IgE-bf either alone or in combination with IL-1 for the treatment or prevention of diseases by stimulating the maturation of myeloid precursor cells.

Description: Maturation of Hemopoietic Cells The invention concerns the use of IgE-binding factor (IgE-bf) for the stimulation of the maturation, i.e. of the differentiation and proliferation, of myeloid precursor cells in context with interleukin-l (IL-1). The invention further concerns a pharmaceutical preparation comprising IgE-bf either alone or in combination with IL-1 for the treatment or prevention of diseases by stimulating the maturation of myeloid precursor cells. Background of the invention Blood contains a heterogeneous population of cells which can be divided into different lineages, i.e. into cells of the myeloid and the lymphoid lineages. The lymphoid cell population consists of B- and T-lymphocytes and their precursors while the myeloid population comprises monocytes, macrophages, erythrocytes, platelets and different types of granulocytes as well as their progenitors. The whole heterogeneous population of blood cells originates from a common set of pluripotent stem cells in the bone marrow. The production of the blood cells, i.e. the hematopoiesis, is a strongly regulated complex process. The pathway of blood cell development is furcated. Starting from a pluripotent stem cell, more and more specialized progenitor cells and finally the fully developped blood cells occur in a stepwise process. The stepwise differentiation of the progenitor cells can be monitored by the occurence of certain patterns of surface markers which are specific for the different cell types. The replication and differentiation of the cells is dependent on the continuous supply of specific protein factors which act as regulators of hematopoiesis. (For review see S.C. Clark and R. Kamen, Science 236: 1229-37, 1987) The progenitor cell of the whole myeloid lineage which is identified in in vitro culture systems is a so called CFU-GEMM (colony-forming unit granulocyte-erythrocyte- monocyte-megakaryocyte). It gives rise to the myeloid precursors BFU-E (burst-forming unit erythrocyte), CFU-MEG (colony-forming unit megakaryocyte), CFU-Eo (colony-forming unit eosinophil) and CFU-GM (colony-forming unit granulocyte- monocyte). The differentiation of CFU-GEMM is triggered by IL-3 (interleukin-3, also named multi-colony stimulating factor or multi-CSF) and GM-CSF (granulocyte- macrophage colony stimualting factor). The myeloid precursor BFU-E further differentiates to CFU-E (colony-forming unit erythrocyte) and, finally, to red blood cells. Protein factors required for these differentiation steps are IL-3, GM-CSF and erythropoietin. CFU-MEG gives rise to the platelet-producing megakaryocy tes in the presence of D -3, GM-CSF and erythropoietin. CFU-GM develops to monocytes/macrophages in the presence of IL-3, GM-CSF and M-CSF (macrophage colony stimulating factor) whereas in the presence of IL-3, GM-CSF and G-CSF (granulocyte colony stimulating factor) granulocytes are produced. G-, M-, GM-CSF, and IL-3 (multi-CSF) have originally been detected in the murine system. Meanwhile the corresponding human factors also have been described. The properties of the mouse and human factors are similar (for review see S.C. Clark and R. Kamen, Science 236: 1229-37, 1987). Diseases caused by a deficiency in the proper regulation of hematopoiesis are known and are of significance. Examples for such diseases are hematopoietic dysfunctions such as dyserythropoiesis, refractory anemia, or dyshematopoiesis. Another problem relating to hematopoiesis is the slow repair in aplasya after bone marrow transplantation. Mainly the occurence of granulocytes in the blood needs at least a few weeks after grafting. Cells of the myeloid lineage can also give rise to tumors. These tumors are leukemias of un- differentiated myeloid cells such as myelomonocytic leukemia or myeloid acute leukemia. Object of the invention It is an object of the invention to provide means for the regulation of hematopoiesis in individuals with a hematopoietic dysfunction. Another object is to provide means for the treatment of tumours of undifferentiated myeloid cells by differentiating the cells to a non-malignant state. Surprisingly, the well known 25 kD IgE-binding factor (25 kD IgE-bf), also named soluble CD23 (sCD23), induces the maturation of myeloid precursor cells which are pretreated with IL-1. Detailed description of the invention The invention concerns a pharmaceutical preparation comprising effective amounts of the 25 kD IgE-bf having the amino acid sequence with the Sequence Identification (SEQ ID) No. 1 shown in the Sequence Listing, or of a pharmacologically active variant, fragment or derivative thereof and of IL-1 or of a pharmacologically active variant, fragment or derivative thereof as an admixture for the use together or in separate form for sequential use. Said pharmaceutical preparation is hereinafter also referred to as a pharmaceutical preparation according to the invention. If not otherwise stated, the term 25 kD IgE-bf herein means the 25 kD IgE-bf having the amino acid sequence with the Sequence Identification (SEQ ID) No. 1 shown in the Sequence Listing. The 25 kD IgE-bf or a pharmacologically active variant, fragment or derivative thereof and IL-1 or a pharmacologically active variant, fragment or derivative thereof are known and can be prepared according to known processes. The 25 kD IgE-bf, variants, fragments and derivatives thereof and methods for their production are disclosed e.g. in EP-A-0254249 and EP-A-0205405. IL-1 and methods of producing same are disclosed e.g. in EP-A-0161901 and EP-A-0165654. A variant of the 25 kD IgE-bf is a protein with an altered amino acid sequence in comparison with the amino acid sequence with the SEQ ID No. 1. A variant includes naturally occuring variants, e.g. human allelic variants or variants isolated from non-human mammalian species, e.g. from mouse or monkey. A variant also includes an artificially made variant. 25 kD IgE-bf or a variant thereof is preferably made by means of recombinant DNA technology, e.g. it is produced by the expression in a heterologous host cell. One or more amino acids may be attached to the N- or C-terminus. For example methionine, N-formyl-methionine or N-acetyl-methionine may be attached to the N-terminus, especially when the expression product is obtained from Escherichia coli. An artificially made variant of the IgE-bf of the invention or of a naturally occuring variant thereof includes proteins characterized by the exchange of one or more, about up to 10, of the amino acids of the 25 kD IgE-bf of the invention or of a naturally occuring variant thereof with one or more of other amino acids. A fragment of the 25 kD IgE-bf or of a variant thereof is an amino acid chain having at least 10 and up to 173 successive amino acids in a sequence corresponding to the invention or to the sequence of a variant thereof. Different or identical fragments may be linked covalently by peptide bonds. Fragments of the 25 kD IgE-bf are in particular those of the group consisting of the poly- peptides either starting with amino acids 2 or 3 and ending with the amino acid 174 or starting with the amino acid 14 and ending with amino acid 140 of the amino acid sequence with the SEQ ID No. 1. The most preferred fragment is characterized in that it consists of the amino acids 3 to 174. This fragment can be found in addition to the 25 kD IgE-bf of the invention in supernatants of RPMI8866 cells, and thus represents a naturally occuring fragment. It has the same activity as the 25 kD IgE-bf. Within the meaning of a fragment of the 25 kD IgE-bf are also fragments of variants of the 25K IgE-bf. Derivatives of the 25 kD IgE-bf or of a variant thereof are such where functional groups, such as amino, hydroxyl, mercapto or carboxyl groups, are derivatized, e.g. glycosylated, acylated, amidated or esterified, respectively. In glycosylated derivatives an oligosaccharide is usually linked to asparagine, serine, threonine and/or lysine. Acylated derivatives are especially acylated by a naturally occuring organic or inorganic acid, e.g. acetic acid, phosphoric acid or sulfuric acid. Usually the N-terminal amino group or hydroxy groups, especially of tyrosine or serine, are acylated. Esters are those of naturally occuring alcohols, e.g. methanol or ethanol. Another derivative of the 25 kD IgE-bf or of a variant thereof is N-terminally extended with methionine, N-formyl-methionine or N-Acetyl-methionine. Such a derivative can be obtained if recombinant 25 kD IgE-bf or a variant thereof is expressed in procaryotes. Further derivatives are salts, especially pharmaceutically acceptable salts, for example metal salts, such as alkali metal and alkaline earth metal salts, e.g. sodium, potassium, magnesium, calcium or zink salts, or ammonium salts formed with ammonia or a suitable organic amine, such as a lower alkylamine, e.g. triethylamine, hydroxy-lower alkylamine, e.g. 2-hydroxyethylamine, and the like. The term derivative according to the present invention includes also derivatives of a variant or a fragment of the 25 kD IgE-bf. A pharmacologically active variant, fragment or derivative of the 25 kD IgE-bf is such having a measurable stimulating influence on the maturation of myeloid precursors which are treated at the same time or pretreated with IL-1 or a pharmacologically active variant, fragment or derivative thereof. The term IL-1 comprises IL-1 purified from the supernatant of mammalian cells which naturally produce IL-1, e.g. from monocytes, optionally after stimulating the IL-1 production in such cells. IL-1 may be derived from different species, e.g. from human, monkey or mouse, preferentially from human. IL-1 also comprises recombinant IL-1, e.g. recombinant IL-lα or recombinant IL-lβ, produced e.g. in E. coli or mammalian cells. A variant of IL-1 includes naturally occuring variants, e.g. human allelic variants or variants isolated from non-human mammalian species, e.g. from mouse or monkey. A variant also includes an artificially made variant. The meaning of a derivative of IL-1 is in accordance with the meaning of a derivative of the 25 kD IgE-bf given hereinbefore. Included within the scope of the present invention are also derivatives of variants or fragments of IL-1. A pharmacologically active variant, fragment or derivative of IL-1 is defined in vitro by a measurable stimulating influence on the maturation, i.e. the proliferation and differentiation, of myeloid precursors which are at the same time or subsequently treated with the 25 kD IgE-bf or a pharmacologically active variant, fragment or derivative thereof. A pharmaceutical preparation according to the invention has a stimulating influence on the maturation of myeloid precursors. It comprises effective amounts of the 25 kD IgE-bf or of a pharmacologically active variant, fragment or derivative thereof, preferentially of the 25 kD IgE-bf or the fragment thereof extending from amino acid 3 up to 174 of the sequence with SEQ ID No. 1, and of IL-1 or of a pharmacologically active variant fragment or derivative thereof. Effective amounts of active ingredients of a pharmaceutical preparation according to the invention are suitable to stimulate the maturation of myeloid precursors. A pharmaceutical preparation according to the invention comprises IL-1 or an equivalent amount of a pharmacologically active variant, fragment or derivative thereof and 25 kD IgE-bf or an equivalent amount of a pharmacologically active variant, fragment or derivative thereof, preferentially the 25 kD IgE-bf having the sequence with SEQ ID No. 1 or the fragment thereof extending from amino acid 3 up to 174 in a ratio of about 50 up to about 100 units to about 0.25 up to about 125 ng, preferentially about 25 up to about 100 ng, resepctively. The active ingredients may be admixed or in separate form. The invention also concerns a process for the stimulation of the maturation of myeloid precursors comprising the application of a pharmaceutical preparation according to the invention. Myeloid precursors are hemopoietic cells which are able to maturate after stimulation with appropriate differentiating factors to other myeloid precursors or to mature cells of the myeloid lineage, for example to red blood cells (also named erythrocytes), megakaryocytes, platelets (also named thrombocytes), monocytes, macrophages, eosinophil, neutrophil, and basophil granulocytes. Myeloid precursors are characterized in that they lack the CD2 surface marker and a subset of the myeloid precursors is additionally characterized by the occurence of the CD34 cell surface marker. Methods for the determination of cell surface markers such as CD2 or CD34 are well known in the art, e.g. indirect immunofluorescence techniques. A myeloid precursor which can be stimulated according to the invention may be derived, for example, from mammalia, e.g. mouse, monkey or preferentially human. An example of a myeloid precursor is CFU-GEMM (colony-forming unit granulocyte- erythrocyte-monocyte-megakaryocyte). It gives rise to other myeloid precursors after stimulation with IL-1 or a pharmacologically active variant, fragment or derivative thereof and 25 kD IgE-bf or a pharmacologically active variant, fragment or derivative thereof. Said other myeloid precursors are, for example, BFU-E (burst-forming unit erythrocyte), CFU-MEG (colony-forming unit megakaryocyte), CFU-Eo (colony-forming unit eosinophil), and CFU-GM (colony-forming unit granulocyte-monocyte). The BFU-E further differentiates to the myeloid precursor CFU-E (colony-forming unit erythrocyte) and further to red blood cells in the presence of erythropoietin, IL-1 or a pharmacologically active variant, fragment or derivative thereof and 25 kD IgE-bf or a pharmacologically active variant, fragment or derivative thereof. CFU-GM differentiates to monocytes/macrophages in the presence of IL-1 or a pharma¬ cologically active variant, fragment or derivative thereof and 25 kD IgE-bf or a pharma¬ cologically active variant, fragment or derivative thereof. CFU-GM differentiates alternatively also to granulocytes in the presence of IL-1 or a pharmacologically active variant, fragment or derivative thereof and 25 kD IgE-bf or a pharmacologically active variant, fragment or derivative thereof. CFU-MEG maturates to a platelet producing megakaryocyte in the presence of erythropoietin, IL-1 and 25 kD IgE-bf. CFU-Eo differentiates to granulocytes the presence of 25 kD IgE-bf and IL-1. In all cases, differentiation occurs if 25 kD IgE-bf and IL-1 are present at the same time or if the cells are pre-treated with IL-1 and subsequently treated with 25 kD IgE-bf. Stimulation of the maturation of myeloid precursors is performed in vitro, for example, by the application of a pharmaceutical preparation according to the invention to a cell culture, which comprises myeloid precursors. A cell culture comprising myeloid precursors is obtained from tissue comprising said cells, e.g. from bone marrow, embryonal tissue or blood. Said tissue may be obtained by biopsy and said cell culture may be obtained by homogenisation of the tissue, isolation of myeloid precursor cells, e.g. by centrifugation in a density gradient, and by cultivation the myeloid cells in an appropriate culture medium. Methods for isolating and cultivating lymphatic cells are known in the art. Myeloid precursor cells may be further purified according to conventional methods e.g. by sorting the cells on a cell sorter or on a plastic surface to which the adherent cell population attaches. The adherent cell population then may be treated with a specifically cytotoxic combination of antibodies not directed against prothymocytes but against cell surface markers of the other cells in the adherent population, and with complement. The pharmaceutical preparation is applied in such amount that a final concentration of about 0.25 ng/ml up to about 125 ng/ml, preferentially from about 25 ng/ml up to about 100 ng/ml, of the 25 kD IgE-bf or of an equivalent amount, i.e. an amount having the same activity, of a pharmacologically active variant, fragment or derivative thereof and a final concentration of about 50 to about 100 U/ml of IL-1 or of a pharmacologically acitve variant, fragment or derivative thereof is achieved. If the active ingredients are in separate form, the cells can be preincubated with about 50 to about 100 U/ml of IL-1 or of a pharmacologically active variant, fragment or derivative thereof, washed in conventional manner, e.g. by centrifugation, and subsequently treated with about 0.25 up to about 125 ng/ml, preferentially with about 25 up to about 100 ng/ml, of the 25 kD IgE-bf or of an equivalent amount of a pharmacologically active variant, fragment or derivative thereof, preferentially of the 25 kD IgE-bf having the sequence with SEQ ID No. 1 or the fragment thereof extending from amino acid 3 up to 174. However, stimulation of the maturation of myeloid precursors can also be performed m vivo by the application of a pharmaceutical preparation of the invention to a living organism, e.g. mous, monkey or preferentially human. For this purpose, a pharmaceutical preparation according to the invention may be administered parenterally, for example, intramuscularly, subcutaneously, intravenously, or directly into the tissue in which the maturation of myeloid precursor takes place, e.g. into the bone marrow, usually in dosage unit forms such as ampoules or vials. The amounts of the polypeptides to be administered depends on their specific activities, on the age, weight and general condition of the patient, the type and severity of the disease, the mode of administration and has to be based on the judgement of the physician. In general a dose of between about 10 μg and about 5000 μg of each of the 25 kD IgE-bf, or a pharmacologic¬ ally active variant, fragment or derivative thereof, preferentially of the 25 kD IgE-bf having the sequence with SEQ ID No. 1 or the fragment thereof extending from amino acid 3 up to 174, and 2-4 Mio U of IL-1 or a pharmacologically active variant, fragment or derivative thereof per kg body weight and day may be administered. The stimulation of the maturation of myeloid precursor can lead to the enlargement of a mature myeloid cell pool and/or to the diminution of a myeloid precursor pool in a cell culture or an organism. Accordingly, the present invention concerns the use of a pharmaceutical preparation according to the invention for the stimulation of the maturation of myeloid precursors for the enlargement of a mature myeloid cell pool, e.g. for the treatment or prevention of a disease caused by a dysfunction in myelopoiesis. Included within the scope of diseases caused by a dysfunction in myelopoiesis is dyserythropoiesis, refractory anemia and dyshematopoiesis. The present invention concerns also the use of a pharmaceutical preparation according to the invention for the stimulation of the maturation of myeloid precursors for the acceleration of the repair in aplasya after bone marrow grafting. The invention concerns further the use of a pharmaceutical preparation according to the invention for the stimulation of the maturation of myeloid precursors for the diminution of a myeloid precursor pool, e.g. for the treatment or prevention of a tumour of an undifferentiated myeloid cell, for example of a myelomonocytic leukemia or myeloid acute leukemia, preferentially of a leukemia of a undifferentiated myeloid cell in which the tumour cells contain the CD34 surface marker. In a pharmaceutical preparation according to the invention the active ingredients are present in form of a mixture or in separate form. If the active ingredients are comprised in the pharmaceutical preparation in separate form, they may be administered by separate routes. A pharmaceutical preparation according to the invention, particularly if used for the treatment or prevention of deficiencies in the development of myeloid cells or of leukemias of myeloid precursors, comprises conventional pharmaceutically acceptable carriers that are suitable for parenteral, e.g. intravenous, intramuscular, subcutaneous or intraperitoneal administration and that do not deleteriously interact with the active ingredients. There are suitable vials containing a solid powder, or vials, ampoules and the like containing infusion solutions, preferably aqueous solutions or suspensions, it being possible to prepare these before use, for example from lyophilized preparations that contain the active ingredient alone or together with a carrier, such as mannitol, lactose, glucose, dextrose, albumin and the like. The pharmaceutical preparation may be sterilized and, if desired, mixed with adjuncts, for example preservatives, stabilisers, emulsifiers, solubilisers, buffers and/or salts, such as 0.9 % sodium chloride, for regulating the osmotic pressure. Sterilization can be achieved by sterile filtration through filters of small pore size (0.45 μm diameter or smaller) after which the preparation can be lyophilized, if desired. Antibiotics may also be added in order to assist in preserving sterility. A pharmaceutical preparation according to the invention is dispensed in unit dosage forms, for example ampules, comprising about 1 to about 2000 mg of a pharmaceutically acceptable carrier per unit dosage and about 0.001 to about 100 mg, preferably about 0.1 to about 50 mg, of each of the active ingredients per unit dosage. The invention also concerns a method for the use of the 25 kD IgE-bf or a pharmaco¬ logically active variant, fragment or derivative thereof, preferentially of the 25 kD IgE-bf having the sequence with SEQ ID No. 1 or the fragment thereof extending from amino acid 3 up to 174, either alone or in combination with IL-1 or a pharmacologically active variant, fragment or derivative thereof for the manufacture of a pharmaceutical preparation for the stimulation of the maturation of myeloid precursors in vitro, e.g. in a cell culture, or in vivo, e.g. in an organism such as mouse, monkey or preferentially human. The active ingredients are processed in conventional manner. The invention further concerns a process for the manufacture of a pharmaceutical preparation according to the invention in which the ingredients are processed in conventional manner. Said process is characterized in that the 25 kD IgE-bf or a pharma¬ cologically active variant, fragment or derivative thereof, preferentially the 25K IgE-bf having the sequence with SEQ ID No. 1 or the fragment thereof extending from amino acid 3 up to 174, and optionally IL-1 or a pharmacologically active variant, fragment or derivative thereof are admixed with a pharmaceutically acceptable carrier or, if the active ingredients are in separate form in the pharmaceutical preparation, are separately admixed with a pharmaceutically acceptable carrier. A pharmaceutical composition according to the invention is manufactured according to methods known per se, for example by conventional mixing, dissolving, lyophilizing, freeze-drying and the like processes and contain about 0.1 % to about 100 %, especially from about 1 % to about 50 % of the active substances. The invention concerns further a pack comprising a pharmaceutical preparation according to the present invention optionally together with instructions for its use. In an organism or cell culture which has sufficient IL-1 or is pretreated with IL-1, only the 25 kD IgE-bf or a pharmacologically active variant, fragment or derivative thereof, preferentially of the 25 kD IgE-bf having the sequence with SEQ ID No. 1 or the fragment thereof extending from amino acid 3 up to 174, needs to be administered to stimulate the maturation of myeloid precursors. Likewise, in an organism or cell culture having sufficient 25 kD IgE-bf, only IL-1 or a pharmacologically active variant, fragment or derivative thereof needs to be administered to stimulate the maturation of myeloid precursors. Furthermore, if myeloid precursors, particularly tumor cells, are in a preactivated state and do not need IL-1 to respond to 25 kD IgE-bf also only the 25 kD IgE-bf having the sequence with SEQ ID No. 1 or a pharmacologically active variant, fragment or derivative thereof, preferentially the 25 kD IgE-bf or the fragment extending from amino acid 3 up to 174 needs to be administered to stimulate the maturation thereof. Accordingly, a subject of the present invention is also a method for the stimulation of the maturation of myeloid precursors in a cell culture or an organism, e.g. in mouse, monkey or preferentially in human, not in need of additional IL-1, for example such having sufficient IL-1 or being pretreated with IL-1 or a pharmacologically active variant, fragment or derivative thereof or comprising myeloid tumor cells which do not need IL-1 to respond to 25 kD IgE-bf, comprising administration of the 25 kD IgE-bf or of a pharmacologically active variant, fragment or derivative thereof, preferentially of the 25 kD IgE-bf having the sequence with SEQ ID No. 1 or the fragment thereof extending from amino acid 3 up to 174, in the same manner and amounts as given hereinbefore. Another subject of the present invention is a method for the stimulation of the maturation of myeloid precursors in a cell culture or an organism, e.g. in mouse, monkey or human, preferentially in human, having sufficient 25 kD IgE-bf or a pharmacologically active variant, fragment or derivative thereof, comprising administration of IL-1 or a pharma¬ cologically active variant, fragment or derivative thereof in the same manner and amounts as given hereinbefore. However, in this case the 25 kD IgE-bf must be present at the same time when IL-1 is administered. The meaning of IL-1 and preferred forms thereof is the same as given above. As already mentioned above, the stimulation of the maturation of myeloid precursors can lead to the enlargement of a mature myeloid cell pool and/or to the diminution of a myeloid precursor pool in a cell culture or an organism. Accordingly, the present invention concerns also a method for the stimulation of the maturation of myeloid precursors, for example for the enlargement of a myeloid cell pool, e.g. for the treatment or prevention of a deficiency in the development of myeloid cells, or for the diminution of a myeloid precursor pool, especially of a leukemic myeloid precursor, e.g. for the treatment or prevention of a leukemia of a myeloid precursor in a cell culture or an organism, e.g. mouse, monkey or preferentially in human, not in need of additional IL-1, for example such having sufficient IL-1 or being pretreated with IL-1 or a pharmacologically active variant, fragment or derivative thereof or comprising myeloid tumor cells which do not need IL-1 to respond to 25 kD IgE-bf, comprising administration of the 25 kD IgE-bf or a pharmacologically active variant, fragment or derivative thereof , preferentially of the 25 kD IgE-bf having the sequence with SEQ ID No. 1 or the fragment thereof extending from amino acid 3 up to 174, in the same manner and amounts as given hereinbefore. Likewise, the invention concerns a method for the stimulation of the maturation of myeloid precursors, for example for the enlargement of a myeloid cell pool, e.g. for the treatment or prevention of a deficiency in the development of myeloid cells, or for the diminution of a myeloid precursor pool, especially of a leukemic myeloid precursor pool, e.g. for the treatment or prevention of a leukemia of myeloid precursor in a cell culture or an organism, such as mouse, monkey or preferentially human, comprising sufficient 25 kD IgE-bf or a pharmacologically active variant, fragment or derivative thereof, comprising administration of IL-1 or a pharmacologically active variant, fragment or derivative thereof in the same manner and amounts as given hereinbefore. The invention concerns also the use of the 25 kD IgE-bf or a pharmacologically active variant, fragment or derivative thereof and/or of IL-1 for the manufacture of a pharmaceutical preparation for the stimulation of the maturation of myeloid precursors. The following examples serve to illustrate the invention, however, they are in no way intended to restrict it. Examples In the following examples, recombinant 25 kD IgE-bf having the amino acid sequence with the SEQ ID No. 1 is named rsCD23. 1. Isolation of Bone Marrow Fractions Bone marrow cells are obtained from trochanter marrow fragments of patients undergoing hip replacement or from bone marrow samples of allogenic transplant donors. Mononuclear cells are isolated by centrifugation of a suspension of bone marrow cells in a Ficoll-Hypaque® gradient according to conventional methods. Adherent cells are removed by adherence on plastic surface. Nonadherent cells are then freed from the CD2 + subset using (2-Aminoethyl isothiouronium bromide hydro- bromide)-treated sheep red blood cells as described in Mossolayi et al., J. Immunol. 134: 2400 (1985). The resulting nonadherent CD2 " population is used for the experiments described in Examples 2 and 3. For the preparation of purified CD34 + cells, the nonadherent CD2 " subset is labelled by indirect immunofluorescence technique with anti-CD34 monoclonal antibody (anti-HPCl, Beckton Dickinson) and FITC-conjugated goat anti-mouse antibody. Fluorescence positive cells are then sorted according to Bot et al., Blood 71: 1609 (1988) using FACStar (Beckton Dickinson). The cell fraction obtained contains more than 93 % of CD34 + cells. 2. Proliferative capacity of stimulated nonadherent CD2 ~ cells The proliferative capacity is measured by determining the formation of colonies with more than 50 cells in semi-solid culture-medium. Nonadherent CD2 " bone marrow cells are prepared according to Example 1. 4 x 10 4 cells per well are seeded in 200 μl of Iscove's modified Dulbecco medium containing 1 % methylcellulose (Ludin et al., EMBO J. 6: 109, 1987) at 37°C with 7 % CO 2 in air. The cell cultures in the wells are supplemented with None, rE -lβ (100 U/ml; Glaxo, Geneva), rIL-lβ (100 U/ml) + rIL-3 (10 U/ml; Boehringer Mannheim), rIL-lβ (100 U/ml) + rIL-3 (10 U/ml) + anti-IL-3 monoclonal antibody (mouse anti-human IL-3 monoclonal antibody BL-3M, 1/50 final dilution; Tebu, Paris, France), rsCD23 (25 ng/ml), rsCD23 (25 ng/ml) + rIL-lβ (100 U/ml), rsCD23 (25 ng/ml) + rIL-lβ (100 U/ml) + anti-IL-3 monoclonal antibody, or rsCD23 (25 ng/ml) + rIL-lβ (100 U/ml) + anti-CD23 monoclonal antibody (IOB6; 25 μg/ml; Immunotech, Marseille, France). Colonies in the wells are scored on day 10 after the cultures are started and induced. The colonies have a typical multilineage morphology. The numbers of colonies with more than 50 cells are given in Table 1. Table 1: Some of the colonies are harvested using an Eppendorf® micropipet, centrifuged and stained with Giemsa. This cytological analysis shows that both the cultures induced with rCD23 + rIL-lβ and with rIL-3 + rIL-lβ contain the same percentage (23 % - 29 %, P < 0.01) of basophils containing colonies. 3. Determination of the effect of the sequence of the application of rsCD23 and riOL-l on the proliferation of nonadherent CD2 ' bone marrow cells Nonadherent CD2 " bone marrow cells are prepared according to Example 1. The medium is supplemented with either of rsCD23 (25 μg/ml) or rBL-lβ (50 U/ml) ("Pre-incubation"), cells are cultured at 37°C with 7 % CO 2 for 24 hours in Iscove's modified Dulbecco medium containing 1 % methylcellulose, washed by centrifugation and subsequently cultured for another 24 hours in the same medium which is supplemented with the other factor ("Post-incubation"). The proliferative capacity is determined as in Example 2 and the results are given in Table 2. Table 2: Effect of sequential application of rsCD23 and rIL-1 on colony generation by nonadherent CD2 " marrow cells * Mean + SD from two different experiments. 4. Proliferative capacity of stimulated CD34 + cells The proliferative capacity is measured exactly as in Example 2, except that the CD34 + cells, which are prepared according to Example 1, are used. The results are given in Table 3. Table 3: Culture supplemented with colonies per 2 x 10 3 cells (means ± standard deviation) 5. Proliferative capacity of stimulated CD34 + cells measured by Thymidine uptake Thymidine uptake of CD34 + cells prepared according to Example 1 is determined in liquid cultures. 10 4 cells are cultured in 100 μl of Iscove's modified Dulbecco medium at 37°C with 7 % CO 2 in air. The cell cultures are supplemented with factors as in Example 4. 3 H-Thymidine (spec, activity 1 Ci/mmol; CEA, Gif-sur-Yvette, France) is added in a final dilution of 1 μCi/100 μl (= 37 kBq/100 μl) is added 24 hours after the addition of the factor(s). Uptake of radioactivity is measured according to conventional methods after 24 hours incubation. The results are given in Table 4. Table 4: 10 4 cells Discussion of the results The data hereinbefore clearly demonstrate the ability of rsCD23 to promote the maturation, i.e. proliferation and differentiation, of myeloid precursors in the presence of or after pretreatment with EL-l. Such rsCD23 effect is observed on both nonadherent CD2 " and highly enriched CD34 + cells. The findings also show that rIL-1 induces the ability of myeloid precursor cells to respond to rsCD23. That rsCD23 triggers myeloid precursor cells directly and not via IL-3 induction is proven by the failure of anti-IL3 antibodies to inhibit the maturation of the cells. Sequence Listing SEQ ID No. 1 SEQUENCE TYPE: Polypeptide SEQUENCE LENGTH: 174 amino acids ORIGINAL SOURCE: human B cell EXPERIMENTAL SOURCE: supernatant of CHO cells transformed with pCAL8-BF/ND (EP-A-0 254 249) PROPERTIES: recombinant 25 kD IgE-bf, also named rs CD23. Leu Arg Met Glu Leu Gin Val Ser Ser Gly Phe Val Cys Asn Thr 5 10 15 Cys Pro Glu Lys Trp lie Asn Phe Gin Arg Lys Cys Tyr Tyr Phe 20 25 30 Gly Lys Gly Thr Lys Gin Trp Val His Ala Arg Tyr Ala Cys Asp 35 40 45 Asp Met Glu Gly Gin Leu Val Ser lie His Ser Pro Glu Glu Gin 50 55 60 Asp Phe Leu Thr Lys His Ala Ser His Thr Gly Ser Trp lie Gly 65 70 75 Leu Arg Asn Leu Asp Leu Lys Gly Glu Phe lie Trp Val Asp Gly 80 85 90 Ser His Val Asp Tyr Ser Asn Trp Ala Pro Gly Glu Pro Thr Ser 95 100 105 Arg Ser Gin Gly Glu Asp Cys Val Met Met Arg Gly Ser Gly Arg 110 115 120 Trp Asn Asp Ala Phe Cys Asp Arg Lys Leu Gly Ala Trp Val Cys 125 130 135 Asp Arg Leu Ala Thr Cys Thr Pro Pro Ala Ser Glu Gly Ser Ala 140 145 150 Glu Ser Met Gly Pro Asp Ser Arg Pro Asp Pro Asp Gly Arg Leu 155 160 165 Pro Thr Pro Ser Ala Pro Leu His Ser 170

Claims: Claims: 1. A pharmaceutical preparation comprising effective amounts of the 25 kD IgE-bf having the amino acid sequence with the Sequence Identification (SEQ ID) No. 1 shown in the Sequence Listing, or of a pharmacologically active variant, fragment or derivative thereof and of IL-1 or of a pharmacologically active variant, fragment or derivative thereof as an admixture for the use together or in separate form for sequential use. 2. A pharmaceutical preparation according to claim 1 comprising an effective amount of the 25 kD IgE-bf having the amino acid sequence with the SEQ ID No. 1 shown in the Sequence Listing or of the fragment thereof consisting of the amino acids 3 to 174 of said amino acid sequence. 3. A pharmaceutical preparation according to claim 1 comprising IL-1. 4. A pharmaceutical preparation according to claim 1 comprising IL-lβ. 5. A pharmaceutical preparation according to claim 1 comprising human IL-1. 6. A pharmaceutical preparation according to claim 1 comprising recombinant IL-1. 7. A pharmaceutical preparation according to claim 1 comprising recombinant human IL-lβ. 8. A pharmaceutical preparation according to claim 1 comprising a ratio of about 50 units of EL-l or an equivalent amount of a pharmacologically active variant, fragment or derivative thereof to about 0.25 up to about 250 mg of the 25 kD IgE-bf having the amino acid sequence with the SEQ ID No. 1 or an equivalent amount of a pharmacologically active variant, fra *togm»' ent or derivative thereof. 9. A pharmaceutical preparation according to claim 1 comprising a ratio of about 50 units of IL-1 or an equivalent amount of a pharmacologically active variant, fragment or derivative thereof to about 25 up to about 100 mg of the 25 kD IgE-bf having the amino acid sequence with the SEQ ID No. 1 or an equivalent amount of a pharmacologically active variant, fragment or derivative thereof. 10. A pharmaceutical preparation according to claim 1 wherein the active ingredients are present in form of a mixture. « 11. A pharmaceutical preparation according to claim 1 wherein the active ingredients are present in separate form. 12. A pharmaceutical preparation according to claim 1 in dosage unit form. 13. A pharmaceutical preparation according to claim 1 for parenteral application. 14. A pharmaceutical preparation according to claim 13 for intravenous application. 15. Use of a pharmaceutical preparation according to claim 1 for the stimulation of the maturation of myeloid precursors. 16. Use according to claim 15 in vitro. 17. Use according to claim 15 in vivo. 18. Use according to claim 15 for the stimulation of the maturation of mammalian myeloid precursors. 19. Use according to claim 18 for the stimulation of the maturation of human myeloid precursors. 20. Use according to claim 18 for the stimulation of the maturation of myeloid precursors with CD34 + phenotype. 21. Use according to claim 15 characterized in that the 25K IgE-bf having the amino acid sequence with the SEQ ID No. 1 or a pharmacologically active variant, fragment or derivative thereof is applied in a final concentration from about 0.25 ng/ml up to about 125 ng/ml and IL-1 or a biologiclly active variant, fragment or derivative thereof is applied in a final concentration of about 50 U/ml. 22. Use according to claim 21 characterized in that the 25K IgE-bf or a biologically active variant, fragment or derivative thereof is applied in a final concentration from about 25 ng/ml up to about 100 ng/ml and IL-1 or a pharmacologically active variant, fragment or derivative thereof is applied in a final concentration of about 50 U/ml. 23. Use according to claim 15 for the enlargement of a mature myeloid cell pool. 24. Use according to claim 23 for the treatment or prevention of a dysfunction in myelopoieses. 25. Use according to claim 23 for the treatment or prevention of dyserythropoiesis. 26. Use according to claim 23 for the treatment or prevention of refractory anemia. 27. Use according to claim 23 for the treatment or prevention of dyshematopoiesis. 28. Use according to claim 23 for the accelleration of repair in aplasya after bone marrow grafting. 29. Use according to claim 15 for the diminution of a myeloid precursor pool. 30. Use according to claim 29 for the treatment or prevention of a tumour of an undifferentieted myeloid cell. 31. Use according to claim 30 for the treatment or prevention of a myelomonocytic or myeloid acute leukemia. 32. Use according to claim 30 in which the tumour cells have a CD34 + phenotype. 33. A process for the manufacture of a pharmaceutical preparation according to claim 1 in which the components are processed according to conventional methods. 34. A pack comprising a pharmaceutical preparation according to claim 1 optionally together with instructions for its use. 35. Use of the 25K IgE-bf having the amino acid sequence with the SEQ ED No. 1 or a pharmacologically active variant, fragment or derivative thereof for the stimulation of the maturation myeloid precursors in a cell culture or an organism comprising sufficient IL-1. 36. Use according to claim 35 for the enlargement of a mature myeloid cell cell pool. « 37. Use according to claim 35 for the diminution of a myeloid precursor pool. 38. Use of IL-1 or a pharmacologically active variant, fragment or derivative thereof for the stimulation of the maturation of myeloid precursors in a cell culture or an organism comprising sufficient 25K IgE-bf. 39. Use according to claim 38 for the enlargement of a myeloid precursor cell pool. 40. Use according to claim 38 for the diminution of a myeloid precursor pool. 41. Use of the 25K IgE-bf having the amino acid sequence with the SEQ ID No. 1 or a pharmacologically active variant, fragment or derivative thereof for the manufacture of a pharmaceutical preparation for the stimulation of the maturation of myeloid precursors. 42. Use of EL-l or a biologically active variant, fragment or derivative thereof for the manufacture of a pharmaceutical preparation for the stimulation of the maturation of myeloid precursors. 43. Use according to claim 41 or 42 in which said pharmaceutical preparation is for use in vitro. 44. Use according to claim 41 or 42 in which said pharmaceutical preparation is for use in vivo. 45. A method for the stimulation of the maturation of myeloid precursors comprising the application of a pharmaceutical preparation according to claim 1 to 4. 46. A pharmaceutical preparation as herein described, particularly with reference to the examples. 47. Use of a pharmaceutical preparation according to claim 1 for the stimulation of the maturation of myeloid precursors as herein described, particularly with reference to the examples. 48. Use of the 25K IgE-bf having the amino acid sequence with the SEQ ID No. 1 or a pharmacologically active variant, fragment or derivative thereof as herein described, particularly with reference to the examples. 49. Use of IL-1 or a pharmacologically active variant, fragment or derivative thereof as herein described, particularly with reference to the examples.

Inventors: DEBRE PATRICE, MOSSALAYI MOHAMMAD DJAVAD, DEBRE, PATRICE, MOSSALAYI, MOHAMMAD, DJAVAD
Applicants: CIBA GEIGY AG, CIBA-GEIGY AG
Application year: 1991
Main classification: A61K37
IPC codes: A61K38, A61P7, C07K14